Targeting the Ribosome: taking on platinum resistance in solid ovarian tumors in a safer way!

Release Date:

Today we’ve got Dr. Jonathan Arambula and Dr. Krystle Karoscik of InnovoTex, an oncology therapeutics company developing a platform of smart molecules capable of circumventing drug resistance often seen in treating ovarian cancer. They’re doing it in a safer way – hear about all this and more by listening to the show!

Disclaimer
The information contained in this website and podcast are purely informational and not considered investment recommendations.  Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an
investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information
conveyed in this material is accurate and is under no obligation to update this information as changes occur.

Targeting the Ribosome: taking on platinum resistance in solid ovarian tumors in a safer way!

Title
Targeting the Ribosome: taking on platinum resistance in solid ovarian tumors in a safer way!
Copyright
Release Date

flashback